Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

The role of Body Mass Index in response to therapy in diffuse large B cell lymphoma patients (CROSBI ID 618830)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa

Duletić-Načinović, Antica ; Marijić, Blažen ; Grubešić, Aron ; Sokolić, Žana ; Dobrila - Dintinjana, Renata The role of Body Mass Index in response to therapy in diffuse large B cell lymphoma patients. 2014

Podaci o odgovornosti

Duletić-Načinović, Antica ; Marijić, Blažen ; Grubešić, Aron ; Sokolić, Žana ; Dobrila - Dintinjana, Renata

engleski

The role of Body Mass Index in response to therapy in diffuse large B cell lymphoma patients

Background: Obesity is a well-known risk factor for the development of several types of cancer including lymphomas, but its influence on the course of this disease is fairly unknown. Despite detailed evaluation of disease-associated prognostic factors, little is known about the impact of overweight in therapy outcomes in patients with diffuse large B cell lymphoma (DLBCL). The aim of this study was to analyse the association between Body Mass Index (BMI) and response to therapy in patients who were newly diagnosed as DLBCL. Also, we wanted to investigate a possible clinical usefulness of Body Mass Index as prognostic factor, for treatment response in patients with this disease. Patients and methods: This retrospective single-center analysis included 94 DLBCL patients who were treated with rituximab and standard-dosed antracycline-based chemotherapy as a first-line therapy. BMI was categorized based on current World Health Organization definitions. The primary endpoint of this research was patients response to applied therapy. Results: Among patients with DLBCL the median age was 66 years. 38% were overweight. No significant association was reported between BMI and response to therapy (p=0, 543), International Prognostic Index (p= 0, 712), Eastern Oncology Cooperative Group performance status (p= 0, 835), Ann Arbor stage (p=0, 996) and B symptoms of disease (p=0, 356). Conclussion: BMI was not significantly associated with clinical outcomes among patients with DLBCL. These findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies.

Body Mass Index; lymphomas; prognostic factors; response to therapy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2014.

objavljeno

Podaci o matičnoj publikaciji

Podaci o skupu

6th International Congress of Croatian Association for Protection of Non Ionizing Radiation ; VIIth Meeting of Experts for Influence in Optical Radiations & Electromagnetis Fields on Human ; IInd Meeting of Experts for the Quality of Life Problems in the Senior Population

poster

26.04.2014-27.04.2014

Opatija, Hrvatska

Povezanost rada

Kliničke medicinske znanosti